Bibliographie (2530)
Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiSuccessful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) – Journal of Thrombosis and Haemostasis Commentary: COVID-19 vaccination: Thrombosis can be prevented by prompt treatment, researchers report – Medical University of Vienna
The post Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). appeared first on Links Medicus.
2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiNeurologic, psychiatric conditions common in COVID-19 – CIDRAP Meta-analysis 1: Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives – Journal of Neurology, Neurosurgery & Psychiatry Meta-analysis 2: Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, […]
The post 2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19. appeared first on Links Medicus.
Investigation | Covid 19: How harm reduction advocates and the tobacco industry capitalized on the pandemic to promote nicotine.
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiCovid 19: How harm reduction advocates and the tobacco industry capitalised on the pandemic to promote nicotine – The BMJ Commentaries: Researchers report how the tobacco and e-cigarette industry capitalized on COVID-19 to promote smoking – News Medical AND Investigation discredits studies suggesting lower COVID-19 risk for smokers
The post Investigation | Covid 19: How harm reduction advocates and the tobacco industry capitalized on the pandemic to promote nicotine. appeared first on Links Medicus.
Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta).
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiNeutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 (Beta) by BNT162b2 vaccination – The Lancet Commentary: Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant – The Francis Crick Institute Commentary on Twitter (thread – click for more) “Immune escape” in #DeltaVariant. That’s the latest finding – that #B16172 is as […]
The post Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta). appeared first on Links Medicus.
Six months of COVID vaccines: what 1.7 billion doses have taught scientists.
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiSix months of COVID vaccines: what 1.7 billion doses have taught scientists – Nature See also: Coronavirus (COVID-19) Vaccinations – Our World in Data Related commentary on Twitter • To administer the first half a billion vaccines took 113 days• The second half a billion 30 days• The third half a billion 23 days• […]
The post Six months of COVID vaccines: what 1.7 billion doses have taught scientists. appeared first on Links Medicus.
WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiWHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic – Nature Related: WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations. AND Brazilian town experiment shows mass vaccination can wipe out COVID-19.
The post WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. appeared first on Links Medicus.
RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased b
lundi, 07 juin 2021 02:05 Écrit par Zouhair SouissiTherapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial – The Lancet Related: #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in […]
The post RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. appeared first on Links Medicus.
ANCA-Associated Vasculitis: An Update.
vendredi, 04 juin 2021 13:26 Écrit par Zouhair SouissiANCA-Associated Vasculitis: An Update – Journal of Clinical Medicine
The post ANCA-Associated Vasculitis: An Update. appeared first on Links Medicus.
Target arterial PO2 according to the underlying pathology: a mini-review of the available data in mechanically ventilated patients.
vendredi, 04 juin 2021 13:26 Écrit par Zouhair SouissiEffects of early extubation followed by noninvasive ventilation versus standard extubation on the duration of invasive mechanical ventilation in hypoxemic non-hypercapnic patients: a systematic review and individual patient data meta-analysis of randomized controlled trials – Critical Care
The post Target arterial PO2 according to the underlying pathology: a mini-review of the available data in mechanically ventilated patients. appeared first on Links Medicus.
RCT: Among patients with ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage treated with Rituximab, a reduced-dose glucocorticoids regimen (prednisolone 0.5 mg/kg/d) was noninferior to a high-dose glucocorticoid regimen (p
vendredi, 04 juin 2021 13:26 Écrit par Zouhair SouissiEffect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial – JAMA
The post RCT: Among patients with ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage treated with Rituximab, a reduced-dose glucocorticoids regimen (prednisolone 0.5 mg/kg/d) was noninferior to a high-dose glucocorticoid regimen (prednisolone 1 mg/kg/d) for the induction of disease remission. appeared first on Links Medicus.
![[Preprint] Covid-19 B.1.617.2 variant of concern (Delta) is associated with increased transmissibility compared to B.1.1.7 (Alpha) that will rapidly lead to B.1.617.2 becoming the prevailing variant in the UK.](/media/k2/items/cache/f4db67ec2dbaadd122c4c0b528856935_XS.jpg)
